IMS Debuts Biologics Usage Measure

IMS Health has launched a new tool that provides an understanding at both the molecule and product level of market size, performance and changing biologics usage in more than 70 countries.

The firm says the $120bn worldwide biologics medicines market accounts for more than 28% of the pharmaceutical industry's research and development budget.

Its new IMS MIDAS Global Biologics solution enables analyses of molecules by type, to guide and drive commercial decisions in therapy areas such as oncology, autoimmune disease and diabetes. The system has been developed in consultation with industry associations, and IMS Health says that the launch establishes the first global standard market definition for this sector.

'For companies looking to expand in this market, IMS MIDAS Global Biologics can help them quickly identify biologic molecules, determine their importance in treatment, and understand the forces underlying performance - all key to ensuring effective portfolio strategies and maximizing return on investment,' stated Jim Mahon, General Manager, Product and Portfolio Management.

This is the latest addition to IMS's New Models, New Metrics program, which provides clients with market measurement services, forecasting, scenario modeling, competitive benchmarking and portfolio management activities.

Last month, the company launched a web-based Q&A service to provide healthcare industry market intelligence and insights to newly-founded biopharmaceutical companies.

Web site: www.imshealth.com .